At PSA, Meet The New Deal-Makers (Part 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
At EBI's Pharmaceutical Strategic Alliances conference in New York on Sept. 22, BD experts addressed key issues for their profession as pharma revamps the way it balances internal and external R&D.
You may also be interested in...
AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program
Revenues flat year on year, but profits up 5% in a year of cost savings and late-stage product disappointments.
AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program
Revenues flat year on year, but profits up 5% in a year of cost savings and late-stage product disappointments.
At PSA, Meet The New Deal-Makers (Part 1)
Two of the biopharma industry's newest heads of business development talked with Elsevier Business Intelligence Editor-in-Chief Chris Morrison at the Pharmaceutical Strategic Alliances conference on Sept. 22 in New York.